Klagenfurt am Wörthersee – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 29 Aug 2026 04:14:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Klagenfurt am Wörthersee – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease https://clinicaltrials.eu/trial/study-of-jnj-78934804-guselkumab-and-golimumab-versus-guselkumab-in-adults-with-moderately-to-severely-active-crohn-s-disease/ Sat, 08 Aug 2026 04:43:19 +0000 https://clinicaltrials.eu/trial/study-of-jnj-78934804-guselkumab-and-golimumab-versus-guselkumab-in-adults-with-moderately-to-severely-active-crohn-s-disease/ Crohn’s Disease is a long‑lasting condition that causes inflammation in the digestive tract, leading to abdominal pain, diarrhea, weight loss and fatigue. The study focuses on people whose disease is moderately to severely active, meaning symptoms are frequent and affect daily life. The investigational medicine being tested is called JNJ-78934804, which contains two active substances, guselkumab and golimumab. It is given as a liquid that is injected subcutaneous (under the skin) using a pre‑filled syringe. For comparison, another group receives only guselkumab in the same type of injection.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

]]> Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis https://clinicaltrials.eu/trial/efficacy-and-safety-of-jnj-78934804-guselkumab-and-golimumab-in-adults-with-moderately-to-severely-active-ulcerative-colitis/ Sat, 08 Aug 2026 04:43:19 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-of-jnj-78934804-guselkumab-and-golimumab-in-adults-with-moderately-to-severely-active-ulcerative-colitis/ The study focuses on ulcerative colitis, a condition where the lining of the large intestine becomes inflamed, causing diarrhea, abdominal pain, and bleeding. The trial includes people whose disease is moderate to severe, meaning symptoms are frequent and affect daily life. The investigational medicine is identified as JNJ-78934804, which contains two active substances, guselkumab and golimumab, and is given as a subcutaneous injection (a shot under the skin). For comparison, participants may receive the approved drug guselkumab alone, also given as a subcutaneous injection.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

]]> A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis https://clinicaltrials.eu/trial/study-of-ataciguat-to-slow-progression-of-moderate-calcific-aortic-valve-stenosis-in-adults/ Mon, 03 Aug 2026 10:45:20 +0000 https://clinicaltrials.eu/trial/study-of-ataciguat-to-slow-progression-of-moderate-calcific-aortic-valve-stenosis-in-adults/ People with Moderate Calcific Aortic Valve Stenosis have a heart valve that becomes thick and stiff, making it harder for blood to flow from the heart to the rest of the body. The study is testing an oral medication called Ataciguat, which is taken as a capsule each day, and comparing it with a placebo that looks the same but contains no active drug.

The purpose of the study is to find out whether the medication can slow the narrowing of the valve and improve the ability to exercise. Participants are randomly assigned to receive either the study drug or the placebo for about a year, with regular clinic visits. During the study, doctors will use an echocardiogram (an ultrasound picture of the heart) to see how big the valve opening is, and a peak VO2 test, measured during a CPET (a breathing and heart test done while exercising), to check how well the body uses oxygen. A CT scan (a detailed X‑ray picture) will also be performed to look at calcium buildup in the valve. If the valve becomes too narrow, doctors may discuss procedures such as TAVR (a catheter‑based valve replacement) or SAVR (surgical valve replacement).

Throughout the trial, participants will be monitored for any side effects, and safety checks will be done at each visit. The study team will collect information about health changes and any additional treatments needed, while keeping participants’ personal information confidential.

]]> High-Dose Colecalciferol for 28-Day Mortality in Critically Ill Adults with Severe Vitamin D Deficiency https://clinicaltrials.eu/trial/study-to-evaluate-the-effect-of-colecalciferol-on-survival-in-critically-ill-adults-with-severe-vitamin-d-deficiency/ Mon, 03 Aug 2026 10:44:36 +0000 https://clinicaltrials.eu/trial/study-to-evaluate-the-effect-of-colecalciferol-on-survival-in-critically-ill-adults-with-severe-vitamin-d-deficiency/ This clinical trial is studying adult critically ill patients with severe vitamin D deficiency, a condition in which the body has very low levels of vitamin D and the person is seriously unwell. The study is testing colecalciferol, a form of vitamin D3, given as oral drops, and comparing it with placebo. The purpose of the study is to find out whether a high dose of vitamin D3 can improve recovery and reduce the chance of death in the first 28 days after treatment.

In this study, people receive either the vitamin D3 drops or placebo, and the care team follows their progress over time. The study looks at what happens during the hospital stay and after discharge, including survival, time in intensive care, time in the hospital, and later health problems such as infections, falls, fractures, and kidney stones. It also checks for possible side effects of high vitamin D, such as hypercalcemia, which means too much calcium in the blood.

]]> Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation https://clinicaltrials.eu/trial/comparing-sotorasib-and-pembrolizumab-with-chemotherapy-for-patients-with-advanced-non-small-cell-lung-cancer-and-kras-g12c-mutation/ Mon, 03 Aug 2026 10:43:53 +0000 https://clinicaltrials.eu/trial/comparing-sotorasib-and-pembrolizumab-with-chemotherapy-for-patients-with-advanced-non-small-cell-lung-cancer-and-kras-g12c-mutation/ This study focuses on individuals with Nonsquamous Non-Small Cell Lung Cancer, a type of lung cancer, specifically those at stage IV or advanced stage IIIB/C. The research is for patients whose tumors do not show high levels of PD-L1, a protein used to help the immune system find cancer, and instead have a specific genetic change known as a KRAS p.G12C mutation. The purpose of the study is to compare the effectiveness of two different treatment approaches used as a first-line therapy.

One group will receive sotorasib combined with a platinum doublet, which refers to a combination of two drugs like carboplatin and pemetrexed. The other group will receive pembrolizumab along with the same platinum doublet. Other medications, such as folic acid, hydroxocobalamin, dexamethasone, and antiemetics, may be used to support the treatment and manage side effects. During the study, the time until the cancer grows or worsens and the total length of time patients live are monitored.

]]> A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-levosimendan-in-patients-with-pulmonary-hypertension-and-heart-failure-with-preserved-ejection-fraction/ Mon, 03 Aug 2026 10:43:46 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-levosimendan-in-patients-with-pulmonary-hypertension-and-heart-failure-with-preserved-ejection-fraction/ This study focuses on individuals living with Pulmonary Hypertension, a condition where the blood pressure in the arteries of the lungs is too high, specifically in those who also have Heart Failure with Preserved Ejection Fraction. This type of heart failure occurs when the heart muscle becomes stiff and cannot relax properly to fill with blood between beats, even though the heart’s ability to pump blood out remains relatively normal. The purpose of the study is to evaluate the effectiveness and safety of a medication called levosimendan compared to a placebo.

Participants in the study will be assigned to receive either the active medication, levosimendan, or a placebo, which is an inactive substance, through an oral hard gelatin capsule. This assignment is done through a randomized process, meaning it is determined by chance, and a double-blind method, where neither the participants nor the researchers know which substance is being administered. The treatment period lasts for 26 weeks, during which the effects on physical activity and general health are monitored.

]]> Comparison of dupilumab and tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps. https://clinicaltrials.eu/trial/comparison-of-dupilumab-and-tezepelumab-for-the-treatment-of-chronic-rhinosinusitis-with-nasal-polyps/ Mon, 03 Aug 2026 10:43:43 +0000 https://clinicaltrials.eu/trial/comparison-of-dupilumab-and-tezepelumab-for-the-treatment-of-chronic-rhinosinusitis-with-nasal-polyps/ This study is designed to compare the effectiveness of two different medications for treating Chronic Rhinosinusitis with Nasal Polyps. This condition involves long-term inflammation of the sinuses and the growth of noncancerous growths, called nasal polyps, inside the nasal passages. The two medications being studied are dupilumab and tezepelumab, which are both administered through a subcutaneous injection, meaning they are injected into the fatty tissue just under the skin.

The purpose of the study is to determine which of these two drugs provides a better improvement in symptoms related to the nasal polyp disease. Over a period of 12 months, participants will receive one of the medications to see how it affects their breathing, their sense of smell, and their overall quality of life. The study will monitor various changes in symptoms and physical health to evaluate how well each treatment works in a real-world setting.

]]> A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a) https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effect-of-olpasiran-on-major-cardiovascular-events-in-patients-with-atherosclerotic-cardiovascular-disease-and-high-levels-of-lipoprotein-a/ Mon, 03 Aug 2026 10:43:26 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effect-of-olpasiran-on-major-cardiovascular-events-in-patients-with-atherosclerotic-cardiovascular-disease-and-high-levels-of-lipoprotein-a/ This study investigates the effects of olpasiran in individuals diagnosed with atherosclerotic cardiovascular disease, a condition where plaque builds up in the arteries, and elevated lipoprotein (a), which is a specific type of fatty protein found in the blood. The purpose of the study is to compare the impact of the study drug against a placebo on the risk of major heart-related issues. These issues include coronary heart disease death, myocardial infarction, or the need for urgent coronary revascularization, which is a procedure used to restore blood flow to the heart.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

]]> Study of budesonide suppositories to treat acute radiation proctitis in men with prostate cancer https://clinicaltrials.eu/trial/study-of-budesonide-suppositories-to-treat-acute-radiation-proctitis-in-men-with-prostate-cancer/ Mon, 03 Aug 2026 10:43:05 +0000 https://clinicaltrials.eu/trial/study-of-budesonide-suppositories-to-treat-acute-radiation-proctitis-in-men-with-prostate-cancer/ This study focuses on individuals with prostate carcinoma, which is a type of cancer affecting the prostate gland. Some of these individuals may experience acute radiation proctitis, a condition involving inflammation of the rectum caused by radiation therapy. This inflammation can lead to symptoms such as rectal pain, diarrhea, and bleeding.

The purpose of the study is to evaluate how well a rectal treatment works for these symptoms. Participants will be assigned to receive either budesonide, which is a type of steroid medication, or a placebo. Both medications will be administered as a suppository, which is a small, solid medicated piece inserted into the rectum for absorption. The study will take place over eight weeks, with the medication used once every day.

]]> A study testing trimodulin in hospitalized adult patients with community-acquired pneumonia including COVID-19 pneumonia https://clinicaltrials.eu/trial/a-study-testing-trimodulin-in-hospitalized-adult-patients-with-community-acquired-pneumonia-including-covid-19-pneumonia/ Mon, 03 Aug 2026 10:42:31 +0000 https://clinicaltrials.eu/trial/a-study-testing-trimodulin-in-hospitalized-adult-patients-with-community-acquired-pneumonia-including-covid-19-pneumonia/ This study involves patients with community-acquired pneumonia or COVID-19 pneumonia who need to be in the hospital and require oxygen support. Community-acquired pneumonia is a lung infection that people get outside of hospitals or healthcare facilities, while COVID-19 pneumonia is a lung infection caused by the coronavirus. The treatment being tested is called trimodulin, also known by its code name BT588, which is a solution made from human blood that contains three types of antibodies called IgM, IgA, and IgG. These antibodies are proteins that help the immune system fight infections. Some patients will receive trimodulin while others will receive placebo, both given through a vein along with the standard care that all patients normally receive for their lung infection.

The purpose of this study is to find out if trimodulin is effective and safe when added to standard care for treating hospitalized adult patients with community-acquired pneumonia or COVID-19 pneumonia. The study will look at whether patients who receive trimodulin do better than those who receive placebo by measuring how many patients get worse or die during the study period. Patients in the study will receive the treatment through an infusion into a vein over five days.

During the study, doctors will monitor patients for up to 91 days to see how they respond to treatment. They will check if patients need more intensive breathing support or if their condition improves, stays the same, or gets worse. The study will also measure various blood markers related to inflammation, immune system function, and blood clotting to understand how the treatment works in the body. Safety will be carefully watched by recording any unwanted effects that occur during and after the treatment period.

]]> A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment https://clinicaltrials.eu/trial/a-study-of-camizestrant-compared-to-standard-hormone-therapy-for-patients-with-er-positive-her2-negative-early-breast-cancer-after-initial-treatment/ Mon, 03 Aug 2026 10:42:17 +0000 https://clinicaltrials.eu/trial/a-study-of-camizestrant-compared-to-standard-hormone-therapy-for-patients-with-er-positive-her2-negative-early-breast-cancer-after-initial-treatment/ This study is looking at a type of breast cancer called ER-positive HER2-negative early breast cancer. This means the cancer cells have receptors for the hormone estrogen but do not have high levels of a protein called HER2. The study is specifically for people who have an intermediate-high or high chance of the cancer coming back after they have completed their initial treatment, including surgery and possibly radiation, and who currently show no signs of disease. The main treatment being tested is camizestrant, which is also known by its code name AZD9833. This is a newer type of medicine that works by breaking down estrogen receptors in cancer cells. Camizestrant will be compared to standard hormone treatments, which include medicines called aromatase inhibitors such as anastrozole, letrozole, and exemestane, or a medicine called tamoxifen. Some people in the study may also receive an additional medicine called abemaciclib. For people who have not gone through menopause, treatment with medications called goserelin, triptorelin, or leuprorelin acetate may be given to stop the ovaries from making hormones.

The purpose of this study is to find out if camizestrant, either alone or combined with abemaciclib, works better than standard hormone treatments, either alone or combined with abemaciclib, in preventing breast cancer from coming back. The study will measure how long people remain free from invasive breast cancer returning. People taking part in this study will be assigned by chance to receive either camizestrant or one of the standard hormone treatments. The treatment will continue for a period of time, and people will be monitored regularly to check how well the treatment is working and to watch for any unwanted effects.

During the study, doctors will check for any side effects that occur, perform blood tests, and measure vital signs like blood pressure and heart rate. People in the study will also be asked questions about their quality of life and how the side effects of treatment affect them in their daily lives. Blood samples may be taken to measure the amount of camizestrant in the blood. The study will track whether the cancer comes back, spreads to other parts of the body, or if a new cancer develops, as well as overall survival.

]]> Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation https://clinicaltrials.eu/trial/study-of-revumenib-and-chemotherapy-for-patients-with-newly-diagnosed-acute-myeloid-leukemia-with-npm1-gene-mutation/ Mon, 03 Aug 2026 10:41:50 +0000 https://clinicaltrials.eu/trial/study-of-revumenib-and-chemotherapy-for-patients-with-newly-diagnosed-acute-myeloid-leukemia-with-npm1-gene-mutation/ This study involves people with newly diagnosed acute myeloid leukemia (a type of blood cancer where abnormal white blood cells grow rapidly in the bone marrow) who have a specific change in their genes called an NPM1 mutation. The treatment being tested includes Revumenib (also known by its code name SNDX-5613), which is an experimental medicine given as tablets by mouth, combined with standard intensive chemotherapy medicines. The chemotherapy medicines used in this study include daunorubicin hydrochloride, idarubicin hydrochloride, and cytarabine, which are given through a vein. Some participants will receive Revumenib along with chemotherapy, while others will receive placebo along with chemotherapy.

The purpose of this study is to find out if adding Revumenib to intensive chemotherapy helps people with this type of leukemia live longer without their disease getting worse compared to chemotherapy alone, and to see if this combination helps more people achieve complete remission with no detectable signs of cancer cells remaining in their bone marrow. During the study, participants will receive their assigned treatment and will be monitored regularly to check how well the treatment is working and to watch for any side effects. The study will track various outcomes including how long participants live, how long they remain in remission, and how many participants achieve complete remission with no measurable remaining disease.

The study will also carefully monitor the safety of the treatment by recording any unwanted effects that occur, checking blood test results regularly, and performing heart function tests and other examinations. Doctors will measure treatment success by looking at whether the cancer goes away completely, whether cancer cells can still be detected in the bone marrow or blood using special tests, and how long participants remain free of cancer. The study is expected to continue for several years to gather enough information about the long-term effects of this treatment combination.

]]> A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation https://clinicaltrials.eu/trial/a-study-of-mk-1084-and-drug-combination-versus-pembrolizumab-and-chemotherapy-for-adults-with-advanced-lung-cancer-with-kras-g12c-mutation/ Mon, 03 Aug 2026 10:41:15 +0000 https://clinicaltrials.eu/trial/a-study-of-mk-1084-and-drug-combination-versus-pembrolizumab-and-chemotherapy-for-adults-with-advanced-lung-cancer-with-kras-g12c-mutation/ This study involves people with a specific type of lung cancer called nonsquamous non-small cell lung cancer that has a particular genetic change known as KRAS G12C mutation. The cancer is either advanced, meaning it has grown significantly, or metastatic, meaning it has spread to other parts of the body. Participants in this study have not yet received treatment for their advanced or metastatic lung cancer. The study will test different combinations of medications to see which works better. One treatment combination includes MK-1084, which is given as a tablet or film-coated tablet by mouth, together with MK-3475A, which contains pembrolizumab and is given as an injection under the skin. The other treatment combination includes MK-3475A together with chemotherapy medications called pemetrexed and either carboplatin or cisplatin, which are given through a vein.

The purpose of this study is to compare how well MK-1084 combined with MK-3475A works compared to MK-3475A combined with chemotherapy in treating this type of lung cancer, particularly in people whose tumors show a certain marker called PD-L1. The study will look at how long participants live without their cancer getting worse, how long they live overall, whether their tumors shrink or disappear, and how long any response to treatment lasts. The study will also monitor what side effects occur and whether participants need to stop treatment because of these side effects.

During the study, participants will receive one of the two treatment combinations. They will have regular check-ups where doctors will examine them, take blood samples, and perform scans to see how the cancer is responding to treatment. Participants will also be asked to complete questionnaires about their quality of life, including questions about breathing difficulties, coughing, and chest pain. The doctors will track any health problems that occur during treatment and measure changes in symptoms and overall well-being throughout the study.

]]> Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients https://clinicaltrials.eu/trial/study-of-incobotulinumtoxina-injections-for-prevention-of-chronic-migraine-in-adult-patients/ Mon, 03 Aug 2026 10:40:24 +0000 https://clinicaltrials.eu/trial/study-of-incobotulinumtoxina-injections-for-prevention-of-chronic-migraine-in-adult-patients/ This clinical trial investigates the use of Xeomin (a type of botulinum toxin A) for people with chronic migraine. Chronic migraine is a condition where a person experiences headaches on 15 or more days per month, with at least 8 of these being migraine headaches, for more than 3 months. The study aims to determine if Xeomin injections are effective in reducing the number of days patients experience migraines compared to placebo.

The study medication will be given through intramuscular injections, meaning the medicine is injected directly into muscles. Participants will receive either Xeomin or placebo injections over a period of 6 months. The treatment involves multiple injection sessions, with the medication being administered at specific intervals throughout the study period.

During the trial, participants will need to keep track of their headaches and migraine days using a headache diary. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of other migraine medications. The researchers will also track any side effects that may occur during the treatment period. The total study duration for each participant will be approximately 36 weeks.

]]> Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease https://clinicaltrials.eu/trial/study-of-maridebart-cafraglutide-to-reduce-cardiovascular-problems-in-overweight-or-obese-patients-with-atherosclerotic-cardiovascular-disease/ Mon, 03 Aug 2026 10:39:00 +0000 https://clinicaltrials.eu/trial/study-of-maridebart-cafraglutide-to-reduce-cardiovascular-problems-in-overweight-or-obese-patients-with-atherosclerotic-cardiovascular-disease/ This study focuses on people with atherosclerotic cardiovascular disease (a condition where arteries become hardened and narrowed) who are also overweight or have obesity. The purpose is to evaluate whether a new medication called maridebart cafraglutide (also known as AMG 133) can help reduce heart and blood vessel-related health problems compared to placebo when added to standard treatments.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

]]> Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack https://clinicaltrials.eu/trial/study-on-managing-heart-attack-risk-with-icosapent-ethyl-and-drug-combination-for-patients-at-high-risk-of-another-heart-attack/ Mon, 03 Aug 2026 10:37:09 +0000 https://clinicaltrials.eu/trial/study-on-managing-heart-attack-risk-with-icosapent-ethyl-and-drug-combination-for-patients-at-high-risk-of-another-heart-attack/ This clinical trial is focused on patients who have experienced an Acute Myocardial Infarction, commonly known as a heart attack. The study aims to explore the effectiveness of a more intensive approach to managing risk factors for heart-related issues compared to standard treatments. The trial will involve the use of several medications, including Vazkepa (which contains the active ingredient icosapent ethyl), Colchicine, and Empagliflozin. These medications are taken orally and are intended to help reduce the risk of further heart problems.

The purpose of the study is to evaluate how well these treatments work in preventing serious heart-related events, such as heart attacks, strokes, and heart failure. Participants in the study will be randomly assigned to receive either the intensified treatment or the standard treatment. The study will monitor the time it takes for participants to experience any major heart-related events, such as cardiovascular death, non-fatal heart attacks, or hospitalizations due to heart issues.

The trial is expected to run for several years, with the goal of gathering enough data to determine the effectiveness of the intensified treatment approach. By participating in this study, researchers hope to find better ways to manage heart health and prevent future heart-related problems in individuals who have already experienced a heart attack.

]]> Study on the Effectiveness and Safety of ANX007 Injections for Patients with Geographic Atrophy from Age-Related Macular Degeneration https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-anx007-injections-for-patients-with-geographic-atrophy-from-age-related-macular-degeneration/ Mon, 03 Aug 2026 10:32:56 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-anx007-injections-for-patients-with-geographic-atrophy-from-age-related-macular-degeneration/ This clinical trial is focused on studying a condition called Geographic Atrophy (GA), which is a form of Age-Related Macular Degeneration (AMD). AMD is a common eye condition that affects the macula, the part of the eye responsible for clear central vision. The study is testing a treatment called ANX007, which is given as an injection directly into the eye, a method known as intravitreal injection.

The purpose of the study is to evaluate how effective and safe ANX007 is in improving visual function and clarity in patients with GA. Participants in the study will receive either the ANX007 injection or a placebo. The study will last for 24 months, during which participants will have monthly visits to monitor their progress and any side effects. The main goal is to see if ANX007 can help maintain or improve vision over time.

Throughout the study, researchers will closely observe any changes in vision and any potential side effects. The study will also track the overall safety of the treatment to ensure it is well-tolerated by participants. This research aims to provide valuable insights into the potential benefits of ANX007 for people living with GA due to AMD.

]]> Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis https://clinicaltrials.eu/trial/study-on-the-effects-of-pegozafermin-for-patients-with-nonalcoholic-steatohepatitis-nash-and-fibrosis/ Mon, 03 Aug 2026 10:31:04 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-pegozafermin-for-patients-with-nonalcoholic-steatohepatitis-nash-and-fibrosis/ This clinical trial is focused on studying a liver condition known as Metabolic Dysfunction-Associated Steatohepatitis (MASH), which is also referred to as Nonalcoholic Steatohepatitis (NASH) with fibrosis. This condition involves the buildup of fat in the liver, leading to inflammation and scarring, which can affect liver function. The study will evaluate a treatment called Pegozafermin, which is administered as a solution for injection. Pegozafermin is being compared to a placebo to assess its effectiveness and safety in treating this liver condition.

The purpose of the study is to determine how well Pegozafermin works in improving liver health and reducing the risk of further liver damage. Participants in the study will receive either Pegozafermin or a placebo through a pre-filled syringe, which is injected under the skin. The study will last for a period of up to 36 months, with key assessments taking place at 52 weeks and at the end of the study. During this time, the effects of the treatment on liver health will be closely monitored.

Throughout the study, participants will undergo various assessments, including imaging tests like Magnetic Resonance Imaging (MRI), to measure changes in liver fat and other liver-related health markers. The study aims to provide valuable insights into the potential benefits of Pegozafermin for individuals with MASH/NASH and fibrosis, ultimately contributing to better treatment options for this condition.

]]> Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans https://clinicaltrials.eu/trial/study-on-rimegepant-for-treating-migraine-in-adults-who-cannot-use-triptans/ Mon, 03 Aug 2026 10:30:50 +0000 https://clinicaltrials.eu/trial/study-on-rimegepant-for-treating-migraine-in-adults-who-cannot-use-triptans/ This clinical trial is focused on studying the effectiveness and safety of a medication called Rimegepant for treating migraine attacks in adults who cannot use another type of medication known as triptans. Migraines are severe headaches that can occur with or without warning signs, known as aura, and can last from a few hours to several days if untreated. The study aims to compare how well Rimegepant works in relieving migraine pain compared to a placebo.

Participants in the study will be randomly assigned to receive either Rimegepant or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The main goal is to see if Rimegepant can reduce the intensity of migraine pain within two hours after taking the medication. The study will also look at other factors, such as whether participants need additional medication within 24 hours and how the medication affects their ability to function normally during a migraine attack.

The trial will take place over a period of time, and participants will be monitored to assess the medication’s impact on their migraine symptoms. The study will help determine if Rimegepant is a suitable option for those who cannot use triptans, providing valuable information on its potential benefits and any side effects. The results will contribute to understanding how Rimegepant can be used in managing migraines effectively.

]]> Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications https://clinicaltrials.eu/trial/study-on-rimegepant-for-preventing-migraines-in-adults-with-poor-response-to-oral-preventive-medications/ Mon, 03 Aug 2026 10:30:49 +0000 https://clinicaltrials.eu/trial/study-on-rimegepant-for-preventing-migraines-in-adults-with-poor-response-to-oral-preventive-medications/ This clinical trial is focused on studying migraine headaches, which are severe headaches that can occur with or without warning signs known as aura. The study is testing a treatment called Rimegepant, also known by its code name BHV-3000. Rimegepant is taken as an oral lyophilisate, which means it dissolves in the mouth. The purpose of the study is to evaluate how well Rimegepant works and how tolerable it is for preventing migraines in adults who have not had success with other oral preventive medications.

Participants in the study will be randomly assigned to receive either Rimegepant or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for several weeks, during which participants will take the medication every other day and report the number of migraine days they experience each month.

The main goal is to see if there is a reduction in the number of migraine days per month compared to before the study started. Additionally, the study will look at whether participants experience fewer days with moderate or severe headache pain and any changes in their ability to perform daily activities. The results will help determine if Rimegepant is an effective option for people who have not found relief with other migraine prevention treatments.

]]> Study of Florastamin (18F) PET/CT Imaging for Detection of Significant Prostate Cancer in Patients with Elevated PSA Levels and Unclear MRI Results https://clinicaltrials.eu/trial/study-on-the-use-of-florastamin-18f-pet-ct-for-locating-prostate-cancer-in-patients-with-elevated-psa-levels-and-mri-suspicion/ Mon, 03 Aug 2026 10:30:25 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-florastamin-18f-pet-ct-for-locating-prostate-cancer-in-patients-with-elevated-psa-levels-and-mri-suspicion/ This study focuses on patients with suspected prostate cancer who have elevated PSA (prostate-specific antigen) levels in their blood. The study will evaluate a new imaging method using Florastamin (18F), which is a radioactive substance given through an intravenous injection. This substance is used in combination with PET/CT scanning (a special type of medical imaging that combines two different scanning techniques) to help locate cancer in the prostate.

The purpose of this research is to determine how well Florastamin (18F) can detect significant prostate cancer in patients who have already undergone an MRI (magnetic resonance imaging) scan that showed unclear or low-risk findings. The medication being tested, also known as Prostavue or IASONFC303, is a solution that is injected into a vein. Each participant will receive a single dose of the study medication and undergo imaging procedures.

During the study, patients will receive the imaging agent and undergo a PET/CT scan. The results will be compared with other standard tests that are normally used to diagnose prostate cancer. The study will track how well this new imaging method performs in finding cancer compared to current diagnostic methods, and whether it leads to any changes in how doctors plan to treat their patients.

]]> Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases https://clinicaltrials.eu/trial/study-on-bi-1015550-for-improving-lung-function-in-patients-with-progressive-fibrosing-interstitial-lung-diseases/ Mon, 03 Aug 2026 10:28:39 +0000 https://clinicaltrials.eu/trial/study-on-bi-1015550-for-improving-lung-function-in-patients-with-progressive-fibrosing-interstitial-lung-diseases/ This clinical trial is focused on studying a group of lung diseases known as Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). These diseases cause scarring of the lung tissue, which can lead to breathing difficulties. The trial is testing a new treatment called BI 1015550, which is taken as a film-coated tablet. The purpose of the study is to see if BI 1015550 can help improve lung function in people with these conditions.

Participants in the study will be randomly assigned to receive either the BI 1015550 treatment or a placebo, which looks like the treatment but does not contain the active medicine. The study will last for at least 52 weeks, during which time the effects of the treatment on lung function will be closely monitored. The main goal is to see if BI 1015550 can slow down the decline in lung function compared to the placebo.

Throughout the study, participants will have regular check-ups to assess their lung function and overall health. The trial will also look at other important outcomes, such as the time it takes for any worsening of the lung disease, hospitalizations due to breathing problems, or any other serious health events. This research aims to provide valuable information on the safety and effectiveness of BI 1015550 for people living with Progressive Fibrosing Interstitial Lung Diseases.

]]> Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer https://clinicaltrials.eu/trial/study-on-atezolizumab-and-bevacizumab-for-patients-with-intermediate-stage-liver-cancer/ Mon, 03 Aug 2026 10:27:30 +0000 https://clinicaltrials.eu/trial/study-on-atezolizumab-and-bevacizumab-for-patients-with-intermediate-stage-liver-cancer/ This clinical trial is focused on studying a type of liver cancer known as intermediate-stage hepatocellular carcinoma. The trial is investigating the effectiveness and safety of a combination of two medications, atezolizumab and bevacizumab, compared to a procedure called transarterial chemoembolization, or TACE. Atezolizumab, also known by its code name RO5541267, and bevacizumab are both given as solutions for infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of this study is to determine how well the combination of these medications works in treating this stage of liver cancer and to compare it with the existing treatment method, TACE. Participants in the study will receive either the combination of atezolizumab and bevacizumab or undergo the TACE procedure. The study will monitor various aspects such as the time it takes for the treatment strategy to fail, overall survival rates, and the response of the cancer to the treatment. The study will also look at the safety of the treatments and how they affect the quality of life of the participants.

The trial is expected to run for several years, with an estimated end date in 2027. Participants will be closely monitored throughout the study to assess the effectiveness of the treatments and any potential side effects. The goal is to find a more effective treatment option for patients with this type of liver cancer, potentially improving their outcomes and quality of life.

]]> Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer https://clinicaltrials.eu/trial/study-of-sbp-101-nab-paclitaxel-and-gemcitabine-for-patients-with-metastatic-pancreatic-cancer/ Mon, 03 Aug 2026 10:26:28 +0000 https://clinicaltrials.eu/trial/study-of-sbp-101-nab-paclitaxel-and-gemcitabine-for-patients-with-metastatic-pancreatic-cancer/ This clinical trial is focused on studying a type of cancer called Metastatic Pancreatic Ductal Adenocarcinoma, which is a form of pancreatic cancer that has spread to other parts of the body. The study is testing a new treatment combination to see if it can help patients live longer. The treatment involves a new drug called SBP-101, which is a small molecule that affects the metabolism of certain compounds in the body. This drug is being tested in combination with two other cancer medications, nab-paclitaxel and gemcitabine. Some participants will receive these medications along with SBP-101, while others will receive a placebo instead of SBP-101.

The purpose of the study is to compare the overall survival of patients who receive the combination of SBP-101, nab-paclitaxel, and gemcitabine with those who receive only nab-paclitaxel and gemcitabine. Participants will be randomly assigned to one of the two groups, and neither the participants nor the researchers will know who is receiving SBP-101 or the placebo. The study will involve regular visits to the clinic for treatment and monitoring, and participants will receive the medications through injections or infusions.

The study will continue for a period of time, during which the health and progress of the participants will be closely monitored. The main goal is to see if the addition of SBP-101 can improve the length of time patients live with this type of cancer. The study will also look at other factors, such as how long it takes for the cancer to progress and the overall response to the treatment. Participants will be asked to complete questionnaires about their quality of life during the study.

]]> Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy https://clinicaltrials.eu/trial/study-on-mavacamten-for-adults-with-symptomatic-obstructive-hypertrophic-cardiomyopathy/ Mon, 03 Aug 2026 10:26:07 +0000 https://clinicaltrials.eu/trial/study-on-mavacamten-for-adults-with-symptomatic-obstructive-hypertrophic-cardiomyopathy/ This clinical trial is focused on studying a heart condition called Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). This condition involves the thickening of the heart muscle, which can make it harder for the heart to pump blood. The study will use a treatment called Mavacamten, which is taken as a capsule. Mavacamten is being tested to see if it can help reduce the thickness of the heart wall and the size of the upper heart chamber, known as the atria. The study will use a special imaging technique called Cardiac Magnetic Resonance (CMR) to look at changes in the heart’s structure.

The purpose of this study is to determine if Mavacamten can effectively reduce the thickness of the heart wall and the size of the atria in patients with oHCM. Participants in the study will be randomly assigned to receive either Mavacamten or a placebo, which is a capsule that looks like the medication but does not contain the active ingredient. The study will last for a period of 96 weeks, during which participants will have regular check-ups and imaging tests to monitor their heart condition.

Throughout the study, the impact of Mavacamten on heart function will be assessed, including any improvements in symptoms related to heart failure. The study will also monitor for any other heart-related events to ensure the safety of the treatment. The goal is to see if Mavacamten can provide a beneficial effect on the heart’s structure and function in people with oHCM.

]]> Study on Atezolizumab for Patients with Lung and Liver Cancer Using Digital Health Solutions https://clinicaltrials.eu/trial/study-on-atezolizumab-for-patients-with-lung-and-liver-cancer-using-digital-health-solutions/ Mon, 03 Aug 2026 10:25:42 +0000 https://clinicaltrials.eu/trial/study-on-atezolizumab-for-patients-with-lung-and-liver-cancer-using-digital-health-solutions/ This clinical trial is focused on studying the effects of a treatment called atezolizumab, which is a solution for injection, on various types of cancer. The study involves two groups of participants. The first group includes individuals with advanced forms of lung cancer, specifically metastatic non-small cell lung carcinoma and extensive-stage small-cell lung carcinoma, as well as those with advanced or unresectable hepatocellular carcinoma, a type of liver cancer. The second group consists of individuals who have had surgery for early-stage non-small cell lung cancer.

The purpose of the study is to explore how digital health solutions can impact health outcomes and the use of healthcare resources for people receiving systemic treatment, which is a type of treatment that affects the entire body. In the first group, the study aims to show how a digital patient monitoring system can help manage symptoms for those receiving atezolizumab. In the second group, the study will look at how feasible it is to combine this digital monitoring with atezolizumab treatment administered at home.

Participants in the study will receive either atezolizumab or a placebo. The study will monitor various aspects of health, including symptom management and the number of hospital visits. The trial will also assess the safety and side effects of atezolizumab when used in combination with digital health tools. The study is expected to continue until 2025, with participants being observed over a period of time to gather comprehensive data on the treatment’s effectiveness and impact on quality of life.

]]> Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin https://clinicaltrials.eu/trial/study-on-xevinapant-and-radiotherapy-for-high-risk-head-and-neck-cancer-patients-unable-to-take-high-dose-cisplatin/ Mon, 03 Aug 2026 10:25:37 +0000 https://clinicaltrials.eu/trial/study-on-xevinapant-and-radiotherapy-for-high-risk-head-and-neck-cancer-patients-unable-to-take-high-dose-cisplatin/ This clinical trial is focused on studying a type of cancer called squamous cell carcinoma of the head and neck. This cancer affects areas such as the mouth, throat, and voice box. The study is specifically for patients who have had surgery to remove the cancer but are at high risk of the cancer coming back. These patients are not able to receive a common chemotherapy drug called high-dose cisplatin due to various health reasons. The treatment being tested in this study is a medication called xevinapant, also known by its code name Debio 1143. Xevinapant is given as an oral solution, which means it is taken by mouth in liquid form. The study will compare the effects of xevinapant combined with radiotherapy to a placebo combined with radiotherapy.

The purpose of this study is to see if adding xevinapant to radiotherapy can improve the time patients remain free from cancer after treatment, which is known as disease-free survival. Participants in the study will be randomly assigned to one of two groups. One group will receive xevinapant and radiotherapy, while the other group will receive a placebo and radiotherapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure the results are not biased.

The study will take place over a period of time, with participants receiving treatment and being monitored for any changes in their health. The goal is to determine if xevinapant can help prevent the cancer from returning in patients who are at high risk and cannot receive high-dose cisplatin. This research could provide important information about new treatment options for people with this type of cancer.

]]> Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis https://clinicaltrials.eu/trial/study-on-fazirsiran-for-patients-with-alpha-1-antitrypsin-deficiency-liver-disease-and-mild-fibrosis/ Mon, 03 Aug 2026 10:24:40 +0000 https://clinicaltrials.eu/trial/study-on-fazirsiran-for-patients-with-alpha-1-antitrypsin-deficiency-liver-disease-and-mild-fibrosis/ This clinical trial is focused on studying a condition known as Alpha-1 Antitrypsin Deficiency-Associated Liver Disease, which is a genetic disorder that can lead to liver damage. The study is investigating a treatment called Fazirsiran, also known by its code name TAK-999. Fazirsiran is a type of medication designed to target specific genes in the liver to help reduce the damage caused by this disease. The trial will compare the effects of Fazirsiran with a placebo to understand its safety and effectiveness, particularly in people with mild liver scarring, also known as fibrosis.

The main goal of the study is to evaluate the long-term safety of Fazirsiran, with a special focus on lung health, as the condition can also affect the lungs. Participants in the study will receive either Fazirsiran or a placebo through injections. The study will monitor various health indicators, including lung function and liver health, over a period of time to see how the treatment affects these areas. Participants will undergo regular check-ups and tests to track any changes in their condition.

This study is important for understanding how Fazirsiran can help people with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and to ensure that it is safe for long-term use. By participating in this trial, researchers hope to gather valuable information that could lead to better treatment options for those affected by this genetic disorder.

]]> Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet https://clinicaltrials.eu/trial/study-on-zed1227-for-improving-symptoms-in-celiac-disease-patients-on-a-gluten-free-diet/ Mon, 03 Aug 2026 10:24:06 +0000 https://clinicaltrials.eu/trial/study-on-zed1227-for-improving-symptoms-in-celiac-disease-patients-on-a-gluten-free-diet/ This clinical trial is focused on studying Celiac Disease, a condition where the immune system reacts to gluten, a protein found in wheat, barley, and rye, causing damage to the small intestine. The study aims to evaluate the effectiveness and safety of a new treatment called ZED1227, which is taken in the form of a hard capsule. Participants in the trial will either receive the ZED1227 capsules or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to see if ZED1227 can help improve symptoms of Celiac Disease in individuals who continue to experience symptoms despite following a gluten-free diet. The trial will involve participants taking the capsules for a period of 15 weeks. During this time, participants will continue their usual gluten-free diet and will be asked to report their symptoms using a diary specifically designed for Celiac Disease symptoms.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. The trial will assess the improvement in symptoms such as diarrhea, abdominal pain, bloating, and nausea, as well as any changes in the condition of the small intestine. The study is designed to provide valuable information on whether ZED1227 can be a beneficial treatment for those with Celiac Disease who are not fully relieved by a gluten-free diet alone.

]]> Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression https://clinicaltrials.eu/trial/study-on-the-effects-of-resmetirom-mgl-3196-for-patients-with-non-alcoholic-steatohepatitis-nash-to-improve-liver-health-and-prevent-further-damage/ Mon, 03 Aug 2026 10:23:57 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-resmetirom-mgl-3196-for-patients-with-non-alcoholic-steatohepatitis-nash-to-improve-liver-health-and-prevent-further-damage/ This study examines the effectiveness of resmetirom (also known as MGL-3196) in treating people with Non-Alcoholic Steatohepatitis (NASH), a serious liver condition where fat buildup leads to inflammation and liver damage. NASH occurs when the liver becomes inflamed due to fat accumulation, which can lead to scarring of liver tissue (known as fibrosis) and potentially progress to more severe liver damage.

The study medication resmetirom is taken as a film-coated tablet by mouth once daily. Participants will receive either resmetirom at doses of 60 mg, 80 mg, or 100 mg, or a placebo. The study aims to determine if resmetirom can help resolve NASH and prevent the progression of liver damage. The treatment period lasts for approximately 54 months, during which participants will have regular check-ups to monitor their liver health.

Throughout the study, doctors will use various methods to assess how well the treatment is working, including examining liver tissue samples and using specialized imaging called MRI-PDFF to measure liver fat content. They will also monitor the levels of various substances in the blood that can indicate liver health and track any changes in LDL cholesterol levels. After the main study period, some participants may have the opportunity to continue treatment in a long-term extension phase.

]]> Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations https://clinicaltrials.eu/trial/study-of-datopotamab-deruxtecan-and-pembrolizumab-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-without-actionable-genomic-alterations/ Mon, 03 Aug 2026 10:23:50 +0000 https://clinicaltrials.eu/trial/study-of-datopotamab-deruxtecan-and-pembrolizumab-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-without-actionable-genomic-alterations/ This clinical trial is focused on studying a type of lung cancer known as Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). The study is investigating the effectiveness of a new treatment combination involving two medications: Datopotamab deruxtecan (also known by its code name DS-1062a) and Pembrolizumab (commonly known as Keytruda). These medications are given as a solution through a vein, a method known as intravenous infusion. The trial aims to compare the effects of using both medications together versus using Pembrolizumab alone.

The purpose of the study is to see if the combination of Datopotamab deruxtecan and Pembrolizumab can help patients live longer without their cancer getting worse, compared to those who receive only Pembrolizumab. Participants in the study will be randomly assigned to receive either the combination treatment or Pembrolizumab alone. The study will monitor the participants over a period of time to assess the progression of the disease and overall survival.

Throughout the study, participants will have regular visits to receive their treatment and undergo various tests to monitor their health and the status of their cancer. The study will continue for up to 24 months, and participants will be closely observed to ensure their safety and to gather information on how well the treatments are working. This trial is an important step in exploring new treatment options for people with advanced stages of non-small cell lung cancer.

]]> Study on Dabigatran and Phenprocoumon for Treating Left Ventricular Thrombosis After Heart Attack in Patients with STEMI https://clinicaltrials.eu/trial/study-on-dabigatran-and-phenprocoumon-for-treating-left-ventricular-thrombosis-after-heart-attack-in-patients-with-stemi/ Mon, 03 Aug 2026 10:22:22 +0000 https://clinicaltrials.eu/trial/study-on-dabigatran-and-phenprocoumon-for-treating-left-ventricular-thrombosis-after-heart-attack-in-patients-with-stemi/ This clinical trial is focused on studying the treatment of two heart-related conditions: ST-elevation myocardial infarction (STEMI), which is a type of heart attack, and left ventricular thrombosis, which is a blood clot in the heart’s left ventricle. The study will use two medications: dabigatran etexilate, known by the brand name Pradaxa, and phenprocoumon, known by the brand name Marcoumar. These medications are used to prevent blood clots, and the study aims to see how well they work in resolving blood clots in the heart after a STEMI.

The purpose of the study is to estimate how many patients experience the resolution of the blood clot in the heart and whether they have any new brain infarctions, which are areas of dead tissue due to lack of blood supply, after three months of treatment. The study will compare the effects of dabigatran etexilate and phenprocoumon over a period of three months. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the actual medications.

Participants in the study will take the medication or placebo for up to three months. During this time, they will be monitored for any changes in their condition, including the resolution of the blood clot and any new brain infarctions. The study will also track any bleeding events that occur during the treatment period and for up to one year afterward. This information will help researchers understand the effectiveness and safety of these treatments for patients with left ventricular thrombosis after a STEMI.

]]> Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-comparing-chemotherapy-alone-to-chemotherapy-with-nivolumab-or-nivolumab-and-bms-986205-for-patients-with-muscle-invasive-bladder-cancer/ Mon, 03 Aug 2026 10:22:10 +0000 https://clinicaltrials.eu/trial/study-comparing-chemotherapy-alone-to-chemotherapy-with-nivolumab-or-nivolumab-and-bms-986205-for-patients-with-muscle-invasive-bladder-cancer/ This clinical trial is focused on studying treatments for Muscle-Invasive Bladder Cancer, a type of cancer that affects the bladder muscle. The study is comparing different treatment approaches to see which is more effective. One group of participants will receive standard chemotherapy, which involves using drugs to kill cancer cells. The chemotherapy drugs being used in this study include gemcitabine hydrochloride and cisplatin. Another group will receive chemotherapy combined with a drug called nivolumab, which is an immunotherapy that helps the immune system fight cancer. Some participants may also receive an additional drug known as BMS-986205, which is being tested for its potential to enhance the effects of nivolumab.

The purpose of the study is to determine if adding nivolumab, with or without BMS-986205, to chemotherapy before surgery can improve outcomes for patients with muscle-invasive bladder cancer. Participants will be randomly assigned to one of the treatment groups. After receiving the initial treatment, participants will undergo surgery to remove the bladder cancer. Following surgery, some participants will continue to receive nivolumab, with or without BMS-986205, to see if it helps prevent the cancer from returning.

The study will last for a period of time, during which participants will receive their assigned treatments and be monitored for any changes in their condition. The researchers will be looking at various outcomes, such as the rate of complete response to the treatment, which means no signs of cancer are found after treatment, and event-free survival, which refers to the length of time participants remain free from cancer-related events. The study will also track overall survival and any side effects or adverse events that may occur during the trial.

]]> Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation https://clinicaltrials.eu/trial/study-of-atezolizumab-and-bevacizumab-for-patients-with-high-risk-hepatocellular-carcinoma-after-surgery-or-ablation/ Mon, 03 Aug 2026 10:21:44 +0000 https://clinicaltrials.eu/trial/study-of-atezolizumab-and-bevacizumab-for-patients-with-high-risk-hepatocellular-carcinoma-after-surgery-or-ablation/ This clinical trial is focused on studying a type of liver cancer known as hepatocellular carcinoma (HCC), particularly in patients who are at high risk of the cancer returning after they have had surgery or a procedure called ablation to remove the cancer. The study is testing a combination of two medications, atezolizumab and bevacizumab, to see if they can help prevent the cancer from coming back. Atezolizumab is also known by its code name, RO5541267, and is an antibody that helps the immune system fight cancer. Bevacizumab is another antibody that works by stopping the growth of blood vessels that feed tumors.

The purpose of the study is to compare the effectiveness of the combination of atezolizumab and bevacizumab with a group of patients who will be under active surveillance, meaning they will be closely monitored without receiving the study medications. The study will last for up to 12 months, during which participants will receive the medications through an intravenous (IV) infusion, which means the medicine is given directly into a vein. The study will track how long patients remain free from cancer recurrence and will also monitor overall survival rates and any side effects experienced by participants.

Participants in the study will have regular check-ups and tests to monitor their health and the status of their cancer. The study aims to provide valuable information on whether the combination of atezolizumab and bevacizumab can be an effective treatment option for preventing the return of hepatocellular carcinoma in patients who have already undergone surgery or ablation. This research could potentially lead to new treatment strategies for managing this type of liver cancer.

]]> Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation https://clinicaltrials.eu/trial/study-comparing-adagrasib-and-docetaxel-for-patients-with-advanced-non-small-cell-lung-cancer-with-kras-g12c-mutation/ Mon, 03 Aug 2026 10:17:56 +0000 https://clinicaltrials.eu/trial/study-comparing-adagrasib-and-docetaxel-for-patients-with-advanced-non-small-cell-lung-cancer-with-kras-g12c-mutation/ This clinical trial is focused on studying a type of lung cancer known as Advanced Non-Small Cell Lung Cancer (NSCLC) that has a specific genetic change called the KRAS G12C mutation. The study is comparing two treatments for this condition. One treatment is an investigational drug called Adagrasib, also known by its code name MRTX849, which is taken as a film-coated tablet. The other treatment is a medication called Docetaxel, which is given as an infusion into a vein.

The purpose of the study is to evaluate how effective Adagrasib is compared to Docetaxel in patients who have already received treatment for their lung cancer. Participants in the study will be randomly assigned to receive either Adagrasib or Docetaxel. The study will monitor the participants over time to see how their cancer responds to the treatment and to check for any side effects. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments.

Throughout the study, researchers will collect information on how long patients live without their cancer getting worse, as well as overall survival rates and how patients feel during the treatment. The study will also look at the safety of the treatments by tracking any adverse events or side effects. This information will help determine the best treatment option for patients with this type of lung cancer.

]]> Study on the Effectiveness and Safety of Bevacizumab, Atezolizumab, and RO7247669 in Patients with Resectable Liver Cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bevacizumab-atezolizumab-and-ro7247669-in-patients-with-resectable-liver-cancer/ Mon, 03 Aug 2026 10:16:57 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bevacizumab-atezolizumab-and-ro7247669-in-patients-with-resectable-liver-cancer/ This clinical trial is focused on studying the effects of a treatment for Hepatocellular Carcinoma, a type of liver cancer. The study will explore the use of different combinations of immunotherapy drugs, which are treatments that help the body’s immune system fight cancer. The medications being tested include Avastin (bevacizumab), Tecentriq (atezolizumab), Tiragolumab, and a drug with the code name RO7247669. These drugs are given as a solution through an intravenous (IV) infusion, which means they are administered directly into the bloodstream.

The purpose of the study is to evaluate how effective these immunotherapy combinations are in treating patients with liver cancer that can be surgically removed. Participants in the study will receive one of the treatment combinations before their surgery. The study will monitor the response of the cancer to the treatment and any side effects that may occur. The goal is to see if these treatments can improve the chances of successful surgery and recovery.

Throughout the study, participants will be closely observed by medical professionals to ensure their safety and to gather information on how well the treatments work. The study will continue for several years, allowing researchers to collect comprehensive data on the effectiveness and safety of these immunotherapy combinations for treating Hepatocellular Carcinoma.

]]> Study on the Effectiveness and Safety of AP707 and Naproxen for Patients with Chronic Back Pain https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ap707-and-naproxen-for-patients-with-chronic-back-pain/ Mon, 03 Aug 2026 10:14:53 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ap707-and-naproxen-for-patients-with-chronic-back-pain/ This clinical trial is focused on evaluating the effectiveness and safety of a treatment called AP707 for individuals experiencing chronic back pain. Chronic back pain is a long-lasting pain in the back that persists for at least three months. The study aims to determine how well AP707 works as an additional treatment for managing this type of pain.

Participants in the study will be divided into two groups. One group will receive the AP707 treatment, while the other group will receive a placebo. The study will last for a total of 52 weeks, with assessments at various points to monitor changes in pain levels and overall well-being. The main goal is to see if AP707 can help reduce pain and improve the quality of life for those with chronic back pain.

Throughout the study, participants will be asked to report their pain levels and any changes they experience. The study will also look at other factors such as sleep quality, psychological distress, and overall health. By the end of the study, researchers hope to gather valuable information on the potential benefits of AP707 for managing chronic back pain.

]]> Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels https://clinicaltrials.eu/trial/study-of-datopotamab-deruxtecan-and-pembrolizumab-for-patients-with-advanced-non-small-cell-lung-cancer-with-low-pd-l1-levels/ Mon, 03 Aug 2026 10:14:53 +0000 https://clinicaltrials.eu/trial/study-of-datopotamab-deruxtecan-and-pembrolizumab-for-patients-with-advanced-non-small-cell-lung-cancer-with-low-pd-l1-levels/ This clinical trial is focused on studying treatments for advanced or metastatic non-small cell lung cancer, a type of lung cancer that has spread beyond the lungs. The study involves several medications, including Datopotamab Deruxtecan (also known as Dato-DXd), Pembrolizumab (also known as Keytruda), and platinum-based chemotherapy drugs like Carboplatin, Pemetrexed, and Cisplatin. These treatments are administered as solutions for infusion, meaning they are given directly into the bloodstream through a vein.

The purpose of the study is to compare the effectiveness of different combinations of these treatments. Participants will receive either a combination of Dato-DXd and Pembrolizumab, with or without platinum-based chemotherapy, or a combination of Pembrolizumab, Pemetrexed, and platinum-based chemotherapy. The study aims to determine which combination works best in controlling the cancer and improving survival.

Participants in the study will receive their assigned treatments over a period of time, with regular monitoring to assess how the cancer responds to the treatment. The study will also involve the use of a placebo in some cases. The trial is designed to provide valuable information on the best treatment options for patients with this type of lung cancer, helping to improve future care and outcomes.

]]> Study on the Effectiveness of AP707, Gabapentin, and Capsaicin for Patients with Chronic Pain from Traumatic or Post-Operative Peripheral Neuropathy https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ap707-gabapentin-and-capsaicin-for-patients-with-chronic-pain-from-traumatic-or-post-operative-peripheral-neuropathy/ Mon, 03 Aug 2026 10:14:52 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ap707-gabapentin-and-capsaicin-for-patients-with-chronic-pain-from-traumatic-or-post-operative-peripheral-neuropathy/ This clinical trial is focused on studying the effectiveness and safety of a treatment called AP707 for individuals experiencing chronic pain due to nerve damage from injuries or surgeries. Chronic pain is a long-lasting pain that persists for months or even years, often affecting daily life and activities. The treatment being tested, AP707, is a special spray used under the tongue, which contains an active ingredient called Adezunap. This study aims to see if AP707 can help reduce pain when used alongside other pain medications.

Participants in the study will be divided into two groups. One group will receive the AP707 treatment, while the other group will receive a placebo, which looks and smells like the real treatment but does not contain the active ingredient. The study will last for about a year, during which participants will have regular check-ups to monitor their pain levels and overall health. The goal is to determine if AP707 can effectively reduce pain and improve the quality of life for those suffering from chronic pain due to nerve damage.

Throughout the study, participants will continue to use their regular pain medications, which may include drugs like Gabapentin, Capsaicin, Imipramine, Amitriptyline, and Paracetamol. These medications are commonly used to manage pain and will be optimized for each participant. The study will also assess any changes in psychological well-being, sleep quality, and overall life satisfaction. By the end of the study, researchers hope to gather valuable information on the potential benefits of AP707 for managing chronic pain.

]]> Study on the Effectiveness and Safety of AP707 with Lamotrigine and Amitriptyline for Patients with Chronic Central Neuropathic Pain https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ap707-with-lamotrigine-and-amitriptyline-for-patients-with-chronic-central-neuropathic-pain/ Mon, 03 Aug 2026 10:14:52 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ap707-with-lamotrigine-and-amitriptyline-for-patients-with-chronic-central-neuropathic-pain/ This clinical trial is focused on evaluating the effectiveness and safety of a treatment called AP707 for individuals experiencing chronic pain due to central neuropathy. Central neuropathy is a condition where nerve damage in the central nervous system causes persistent pain. The study aims to determine how well AP707 works as an additional treatment for managing this type of pain.

Participants in the study will receive either the AP707 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for a total of 52 weeks, during which participants will be monitored at various intervals to assess changes in their pain levels and overall well-being. The treatment is administered as a sublingual spray, meaning it is sprayed under the tongue for absorption.

Throughout the study, participants’ pain levels will be measured using a simple scale, and other aspects such as quality of life, sleep quality, and psychological well-being will also be evaluated. The goal is to see if AP707 can provide significant relief from chronic pain and improve the quality of life for those affected by central neuropathy.

]]>